Please assess the completion status of the following clinical trial:

Trial Title: The Efficiency Of The Methotrexate At Patients Affected By Grave Pelade

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. - age 18 to 70 years old~2. - informed consent,~3. - severe type of AA defined as : 3.1 - AA totalis universalis 3.2 - evolving for more than 6 months despite previous treatments including photothérapy (PUVA oru UVB), applications of super potent topical corticosteroid ( clobetasol propionate), applications of minoxidil 5%, or IV pulse corticosteroids 3.3 - DLQI score superior or equal to 10~Exclusion Criteria:~* Pregnant or breast feeding women~* VIH + patients~* active hepatitis B or C~* treatment with immunosuppressant (ciclosporine, mycophénolate mofetil~  , cyclophosphamide, azathioprine, méthotrexate) within 2 months before inclusion~* severe cardiac arythma or severe cardiac insufficiency or severe coronary disease~* liver disorder~* alcool consumption~* renal failure~* Severe diabetes mellitus~* past history of severe infection~* past history of néoplasiae ( excluding BCC),~* Karnofsky index \<à 50 %~* severe lung disorder~* mental impairment~* symptomatic osteoporosis~* blood cytopénia (hémoglobine \< 10 g/l ; leucocytes\< 3000/mm3, platelets\< 100 000/mm3)~* albuminémia \< 25 g/l

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ARM A : METHOTREXATE (Type: PLACEBO_COMPARATOR): Arm A: methotrexate 20 to 25 mg / week for 6 months. Patients who will experience at least a 25% hair regrowth after the month 5 evaluation will continue methotrexate or placebo from month 6 to the end of the study (month 12).~Non responder patients in both arms A and B will be re-randomized to receive from month 6 to the end of the study (month 12):~* methotrexate alone or~* methotrexate associated with prednisone 0.3 mg/Kg/day
- ARM B : PLACEBO (Type: PLACEBO_COMPARATOR): Arm B placebo Patients who will experience at least a 25% hair regrowth after the month 5 evaluation will continue methotrexate or placebo from month 6 to the end of the study (month 12).~Non responder patients in both arms A and B will be re-randomized to receive from month 6 to the end of the study (month 12):~* methotrexate alone or~* methotrexate associated with prednisone 0.3 mg/Kg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).